Efficacy and tolerability of initial triple combination therapy with metformin, dapagliflozin and saxagliptin compared with stepwise add‐on therapy in drug‐naïve patients with type 2 diabetes (TRIPLE‐AXEL study): A multicentre, randomized, 104‐week, open‐label, active‐controlled trial

Aim To evaluate the efficacy and tolerability of an initial triple combination therapy (TCT) compared with conventional stepwise add‐on therapy (SAT) in patients with newly diagnosed type 2 diabetes (T2D). Materials and Methods This multicentre, randomized, 104‐week, open‐label trial randomized 105...

Full description

Saved in:
Bibliographic Details
Published in:Diabetes, obesity & metabolism obesity & metabolism, 2024-09, Vol.26 (9), p.3642-3652
Main Authors: Kim, Nam Hoon, Moon, Jun Sung, Lee, Yong‐ho, Cho, Ho Chan, Kwak, Soo Heon, Lim, Soo, Moon, Min Kyong, Kim, Dong‐Lim, Kim, Tae Ho, Ko, Eunvin, Lee, Juneyoung, Kim, Sin Gon
Format: Article
Language:English
Subjects:
Adverse events
Antidiabetics
clinical trial
Combination therapy
Diabetes
Diabetes mellitus (non-insulin dependent)
DPP‐4 inhibitor
glycaemic control
Hypoglycemia
Metformin
SGLT2 inhibitor
type 2 diabetes
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aim To evaluate the efficacy and tolerability of an initial triple combination therapy (TCT) compared with conventional stepwise add‐on therapy (SAT) in patients with newly diagnosed type 2 diabetes (T2D). Materials and Methods This multicentre, randomized, 104‐week, open‐label trial randomized 105 patients with drug‐naïve T2D (with HbA1c level ≥ 8.0%,
ISSN:1462-8902
1463-1326
1463-1326
DOI:10.1111/dom.15705